<?xml version="1.0" encoding="utf-8"?>
<?xml-stylesheet type="text/xsl" href="/ProjectMundo/style/jats-html.xsl"?>
<!DOCTYPE response>
<article article-type="research-article" dtd-version="1.2" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
 <front>
  <journal-meta>
   <journal-id journal-id-type="publisher-id">
    41467
   </journal-id>
   <journal-id journal-id-type="doi">
    10.1038/41467.2041-1723
   </journal-id>
   <journal-title-group>
    <journal-title>
     Nature Communications
    </journal-title>
    <abbrev-journal-title abbrev-type="publisher">
     Nat Commun
    </abbrev-journal-title>
   </journal-title-group>
   <issn pub-type="epub">
    2041-1723
   </issn>
   <publisher>
    <publisher-name>
     Nature Publishing Group UK
    </publisher-name>
    <publisher-loc>
     London
    </publisher-loc>
   </publisher>
  </journal-meta>
  <article-meta>
   <article-id pub-id-type="publisher-id">
    s41467-024-52894-2
   </article-id>
   <article-id pub-id-type="manuscript">
    52894
   </article-id>
   <article-id pub-id-type="doi">
    10.1038/s41467-024-52894-2
   </article-id>
   <article-categories>
    <subj-group subj-group-type="heading">
     <subject>
      Article
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /692/53/2423
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /692/308/174
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /692/699/67
     </subject>
    </subj-group>
    <subj-group subj-group-type="TechniquePath">
     <subject>
      /82/58
     </subject>
    </subj-group>
    <subj-group subj-group-type="NatureArticleTypeID">
     <subject>
      article
     </subject>
    </subj-group>
   </article-categories>
   <title-group>
    <article-title xml:lang="en">
     Plasma proteomic and polygenic profiling improve risk stratification and personalized screening for colorectal cancer
    </article-title>
   </title-group>
   <contrib-group>
    <contrib contrib-type="author" equal-contrib="yes" id="Au1">
     <name name-style="western">
      <surname>
       Sun
      </surname>
      <given-names>
       Jing
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
     <xref ref-type="author-notes" rid="fn1"/>
    </contrib>
    <contrib contrib-type="author" equal-contrib="yes" id="Au2">
     <name name-style="western">
      <surname>
       Liu
      </surname>
      <given-names>
       Yue
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff4">
      4
     </xref>
     <xref ref-type="aff" rid="Aff5">
      5
     </xref>
     <xref ref-type="author-notes" rid="fn1"/>
    </contrib>
    <contrib contrib-type="author" id="Au3">
     <name name-style="western">
      <surname>
       Zhao
      </surname>
      <given-names>
       Jianhui
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au4">
     <name name-style="western">
      <surname>
       Lu
      </surname>
      <given-names>
       Bin
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff6">
      6
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au5">
     <name name-style="western">
      <surname>
       Zhou
      </surname>
      <given-names>
       Siyun
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au6">
     <name name-style="western">
      <surname>
       Lu
      </surname>
      <given-names>
       Wei
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff4">
      4
     </xref>
     <xref ref-type="aff" rid="Aff5">
      5
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au7">
     <name name-style="western">
      <surname>
       Wei
      </surname>
      <given-names>
       Jingsun
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff4">
      4
     </xref>
     <xref ref-type="aff" rid="Aff5">
      5
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au8">
     <name name-style="western">
      <surname>
       Hu
      </surname>
      <given-names>
       Yeting
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff4">
      4
     </xref>
     <xref ref-type="aff" rid="Aff5">
      5
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au9">
     <name name-style="western">
      <surname>
       Kong
      </surname>
      <given-names>
       Xiangxing
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff4">
      4
     </xref>
     <xref ref-type="aff" rid="Aff5">
      5
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au10">
     <name name-style="western">
      <surname>
       Gao
      </surname>
      <given-names>
       Junshun
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff7">
      7
     </xref>
     <xref ref-type="aff" rid="Aff8">
      8
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au11">
     <name name-style="western">
      <surname>
       Guan
      </surname>
      <given-names>
       Hong
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff7">
      7
     </xref>
     <xref ref-type="aff" rid="Aff8">
      8
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au12">
     <name name-style="western">
      <surname>
       Gao
      </surname>
      <given-names>
       Junli
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff7">
      7
     </xref>
     <xref ref-type="aff" rid="Aff8">
      8
     </xref>
     <xref ref-type="author-notes" rid="fn2"/>
    </contrib>
    <contrib contrib-type="author" corresp="yes" id="Au13">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0002-0120-2371
     </contrib-id>
     <name name-style="western">
      <surname>
       Xiao
      </surname>
      <given-names>
       Qian
      </given-names>
     </name>
     <address>
      <email>
       qxiao3@zju.edu.cn
      </email>
     </address>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
     <xref ref-type="aff" rid="Aff4">
      4
     </xref>
     <xref ref-type="aff" rid="Aff5">
      5
     </xref>
     <xref ref-type="corresp" rid="IDs41467024528942_cor13">
      p
     </xref>
     <xref ref-type="author-notes" rid="fn2"/>
    </contrib>
    <contrib contrib-type="author" id="Au14">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0001-6880-2577
     </contrib-id>
     <name name-style="western">
      <surname>
       Li
      </surname>
      <given-names>
       Xue
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
     <xref ref-type="author-notes" rid="fn2"/>
    </contrib>
    <aff id="Aff1">
     <label>
      1
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/059cjpv64
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.412465.0
      </institution-id>
      <institution content-type="org-division">
       Department of Colorectal Surgery and Oncology (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education)
      </institution>
      <institution content-type="org-name">
       The Second Affiliated Hospital, Zhejiang University School of Medicine
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Hangzhou
     </addr-line>
     <addr-line content-type="state">
      Zhejiang
     </addr-line>
     <country country="CN">
      China
     </country>
    </aff>
    <aff id="Aff2">
     <label>
      2
     </label>
     <institution-wrap>
      <institution-id institution-id-type="GRID">
       grid.13402.34
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 1759 700X
      </institution-id>
      <institution content-type="org-division">
       Department of Big Data in Health Science, School of Public Health and The Second Affiliated Hospital
      </institution>
      <institution content-type="org-name">
       Zhejiang University School of Medicine
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Hangzhou
     </addr-line>
     <country country="CN">
      China
     </country>
    </aff>
    <aff id="Aff3">
     <label>
      3
     </label>
     <institution-wrap>
      <institution-id institution-id-type="GRID">
       grid.419897.a
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 0369 313X
      </institution-id>
      <institution content-type="org-name">
       Center for Medical Research and Innovation in Digestive System Tumors, Ministry of Education
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Hangzhou
     </addr-line>
     <addr-line content-type="state">
      Zhejiang
     </addr-line>
     <country country="CN">
      China
     </country>
    </aff>
    <aff id="Aff4">
     <label>
      4
     </label>
     <institution-wrap>
      <institution content-type="org-name">
       Zhejiang Provincial Clinical Research Center for CANCER
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Hangzhou
     </addr-line>
     <addr-line content-type="state">
      Zhejiang
     </addr-line>
     <country country="CN">
      China
     </country>
    </aff>
    <aff id="Aff5">
     <label>
      5
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/00a2xv884
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.13402.34
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 1759 700X
      </institution-id>
      <institution content-type="org-name">
       Cancer Center of Zhejiang University
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Hangzhou
     </addr-line>
     <addr-line content-type="state">
      Zhejiang
     </addr-line>
     <country country="CN">
      China
     </country>
    </aff>
    <aff id="Aff6">
     <label>
      6
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/059cjpv64
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.412465.0
      </institution-id>
      <institution content-type="org-division">
       Nursing Department
      </institution>
      <institution content-type="org-name">
       The Second Affiliated Hospital of Zhejiang University School of Medicine
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Hangzhou
     </addr-line>
     <addr-line content-type="state">
      Zhejiang
     </addr-line>
     <country country="CN">
      China
     </country>
    </aff>
    <aff id="Aff7">
     <label>
      7
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/00a2xv884
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.13402.34
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 1759 700X
      </institution-id>
      <institution content-type="org-name">
       Cosmos Wisdom Mass Spectrometry Center of Zhejiang University Medical School
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Hangzhou
     </addr-line>
     <addr-line content-type="state">
      Zhejiang
     </addr-line>
     <country country="CN">
      China
     </country>
    </aff>
    <aff id="Aff8">
     <label>
      8
     </label>
     <institution-wrap>
      <institution content-type="org-name">
       Key Laboratory of Precision Medicine in Diagnosis and Monitoring Research of Zhejiang Province
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Hangzhou
     </addr-line>
     <addr-line content-type="state">
      Zhejiang
     </addr-line>
     <country country="CN">
      China
     </country>
    </aff>
   </contrib-group>
   <author-notes>
    <fn fn-type="equal" id="fn1">
     <p>
      These authors contributed equally: Jing Sun, Yue Liu.
     </p>
    </fn>
    <fn fn-type="con" id="fn2">
     <p>
      These authors are jointly supervised this work: Junli Gao, Qian Xiao, Xue Li.
     </p>
    </fn>
    <corresp id="IDs41467024528942_cor13">
     <label>
      p
     </label>
     <email>
      qxiao3@zju.edu.cn
     </email>
    </corresp>
   </author-notes>
   <pub-date date-type="pub" publication-format="electronic">
    <day>
     15
    </day>
    <month>
     10
    </month>
    <year>
     2024
    </year>
   </pub-date>
   <pub-date date-type="collection" publication-format="electronic">
    <month>
     12
    </month>
    <year>
     2024
    </year>
   </pub-date>
   <volume>
    15
   </volume>
   <issue seq="8873">
    1
   </issue>
   <elocation-id>
    8873
   </elocation-id>
   <history>
    <date date-type="registration">
     <day>
      25
     </day>
     <month>
      9
     </month>
     <year>
      2024
     </year>
    </date>
    <date date-type="received">
     <day>
      21
     </day>
     <month>
      2
     </month>
     <year>
      2024
     </year>
    </date>
    <date date-type="accepted">
     <day>
      20
     </day>
     <month>
      9
     </month>
     <year>
      2024
     </year>
    </date>
    <date date-type="online">
     <day>
      15
     </day>
     <month>
      10
     </month>
     <year>
      2024
     </year>
    </date>
   </history>
   <permissions>
    <copyright-statement content-type="compact">
     © The Author(s) 2024
    </copyright-statement>
    <copyright-year>
     2024
    </copyright-year>
    <copyright-holder>
     The Author(s)
    </copyright-holder>
    <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">
     <license-p>
      <bold>
       Open Access
      </bold>
      This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
      <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">
       http://creativecommons.org/licenses/by-nc-nd/4.0/
      </ext-link>
      .
     </license-p>
    </license>
   </permissions>
   <abstract id="Abs1" xml:lang="en">
    <title>
     Abstract
    </title>
    <p id="Par1">
     Uchunguzi huu unahitaji kuchunguza maandishi ya proteomic yanayohusiana na kansa ya koli na rektumi (CRC) na kujenga modeli ya maonyesho ya uhasama wa CRC kwa kujumlia maandishi ya proteomic pamoja na elfu na elfu za si-genetiki na si-genetiki (QCancer-15) ili kubadilisha kwa bora uhusiano wa ukurasa wa hatari na kufafanulia umri wa kuanza kuchunguza kwa kibinafsi. Hapa, kwa kutumia uchaguzi wa mada mbili, tunapokabiliana 15 biomakasi ya protini kama vichujio vya kuanza kujenga anwani ya hatari ya protini (ProS). Modeli ya maonyesho ya hatari yanayokujumlia maandishi ya proteomic pamoja na anwani ya hatari ya polygenic (PRS) na anwani ya hatari ya QCancer-15 (QCancer-S) ina uwezo bora (C-statistic: 0.79 vs. 0.71,
     <italic>
      P
     </italic>
     = 4.94E–03 katika kikundi cha kujifunza; 0.75 vs 0.69,
     <italic>
      P
     </italic>
     = 5.49E–04 katika kikundi cha kuthibitisha) na faida ya kutoa kwa kibinafsi zaidi kuliko QCancer-S pekee. Modeli ya yenyewe ina kubadilisha kwa sana ukurasa wa hatari ya uhasama wa CRC. Wanachama wenye anwani ya hatari ya ProS, PRS, au yenyewe ya kujumlia ya juu huamalizwa kuanza kuchunguza umri 46, 41, au kabla ya 40 miaka. Katika kazi hii, kujumlia maandishi ya proteomic ya damu pamoja na PRS na QCancer-15 ina uwezo bora kwa uhusiano wa ukurasa wa hatari na maana ya kliniki kwa kuanza kuchunguza ukurasa wa hatari ya CRC, ambayo inaweza kusaidia katika mchakato wa kufanya maamuzi kwa kuchunguza CRC.
    </p>
   </abstract>
   <abstract abstract-type="ShortSummary" id="Abs2" xml:lang="en">
    <p id="Par2">
     Non-invasive approaches for risk stratification and screening remain crucial for colorectal cancer (CRC). Here, the authors develop a model for CRC risk stratification by integrating plasma proteomics data with polygenic risk score and QCancer-15 risk score, which could guide recommendations for earlier screening of high-risk populations.
    </p>
   </abstract>
   <kwd-group kwd-group-type="hierarchical" vocab="FoR" vocab-identifier="ANZSRC 2008">
    <kwd content-type="term" vocab-term-identifier="11">
     Medical and Health Sciences
    </kwd>
    <nested-kwd>
     <kwd content-type="term" vocab-term-identifier="1117">
      Public Health and Health Services
     </kwd>
    </nested-kwd>
   </kwd-group>
   <funding-group>
    <award-group>
     <funding-source>
      <institution-wrap>
       <institution>
        National Natural Science Foundation of China (National Science Foundation of China)
       </institution>
       <institution-id institution-id-type="doi" vocab="open-funder-registry">
        https://doi.org/10.13039/501100001809
       </institution-id>
      </institution-wrap>
     </funding-source>
     <award-id award-type="FundRef grant">
      82072360
     </award-id>
     <award-id award-type="FundRef grant">
      82373234
     </award-id>
     <principal-award-recipient>
      <name name-style="western">
       <surname>
        Xiao
       </surname>
       <given-names>
        Qian
       </given-names>
      </name>
     </principal-award-recipient>
     <principal-award-recipient>
      <name name-style="western">
       <surname>
        Xiao
       </surname>
       <given-names>
        Qian
       </given-names>
      </name>
     </principal-award-recipient>
    </award-group>
   </funding-group>
   <custom-meta-group>
    <custom-meta>
     <meta-name>
      publisher-imprint-name
     </meta-name>
     <meta-value>
      Nature Portfolio
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      volume-issue-count
     </meta-name>
     <meta-value>
      1
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-article-count
     </meta-name>
     <meta-value>
      8873
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-toc-levels
     </meta-name>
     <meta-value>
      0
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-pricelist-year
     </meta-name>
     <meta-value>
      2024
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-copyright-holder
     </meta-name>
     <meta-value>
      Springer Nature Limited
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-copyright-year
     </meta-name>
     <meta-value>
      2024
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-contains-esm
     </meta-name>
     <meta-value>
      Yes
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-numbering-style
     </meta-name>
     <meta-value>
      Unnumbered
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-registration-date-year
     </meta-name>
     <meta-value>
      2024
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-registration-date-month
     </meta-name>
     <meta-value>
      9
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-registration-date-day
     </meta-name>
     <meta-value>
      25
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-toc-levels
     </meta-name>
     <meta-value>
      0
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      toc-levels
     </meta-name>
     <meta-value>
      0
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      volume-type
     </meta-name>
     <meta-value>
      Regular
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-product
     </meta-name>
     <meta-value>
      NonStandardArchiveJournal
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      numbering-style
     </meta-name>
     <meta-value>
      Unnumbered
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-grants-type
     </meta-name>
     <meta-value>
      OpenChoice
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      metadata-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      abstract-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      bodypdf-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      bodyhtml-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      bibliography-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      esm-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      online-first
     </meta-name>
     <meta-value>
      false
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      pdf-file-reference
     </meta-name>
     <meta-value>
      BodyRef/PDF/41467_2024_Article_52894.pdf
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      pdf-type
     </meta-name>
     <meta-value>
      Typeset
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      target-type
     </meta-name>
     <meta-value>
      OnlinePDF
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-type
     </meta-name>
     <meta-value>
      Regular
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-type
     </meta-name>
     <meta-value>
      OriginalPaper
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-primary
     </meta-name>
     <meta-value>
      Science, Humanities and Social Sciences, multidisciplinary
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-secondary
     </meta-name>
     <meta-value>
      Science, Humanities and Social Sciences, multidisciplinary
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-secondary
     </meta-name>
     <meta-value>
      Science, multidisciplinary
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-collection
     </meta-name>
     <meta-value>
      Science (multidisciplinary)
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      open-access
     </meta-name>
     <meta-value>
      true
     </meta-value>
    </custom-meta>
   </custom-meta-group>
  </article-meta>
 </front>
 <body>
  <sec id="Sec1" sec-type="introduction">
   <title>
    Ujumbe
   </title>
   <p id="Par3"/>
   <p id="Par4"/>
   <p id="Par5">
    <fig id="Fig1" position="float">
     <label>
      Fig. 1
     </label>
     <caption xml:lang="sw">
      <title>
       Ushahidi wa mchezaji wa utafiti kuu.
      </title>
      <p>
       BMI ni indeksi ya uzito wa mwili, TDI ni indeksi ya Townsend ya ukatili, PRS ni anwani ya tukio la genetiki, RAP ni muda wa kuharibu tukio.
      </p>
     </caption>
     <graphic href="/ProjectMundo/MediaObjects/10X1038_s41467-024-52894-2/41467_2024_52894_Fig1_HTML.png" mime-subtype="PNG" specific-use="web"/>
    </fig>
   </p>
  </sec>
  <sec id="Sec2" sec-type="results">
   <title>
    Matokeo
   </title>
   <sec id="Sec3">
    <title>
     Alama za proteomu za CRC
    </title>
    <p id="Par6"/>
   </sec>
   <sec id="Sec4">
    <title>
     Uundaji wa anwani za hatari
    </title>
    <p id="Par7">
     <fig id="Fig2" position="float">
      <label>
       Fig. 2
      </label>
      <caption xml:lang="sw">
       <title>
        Matokeo ya 15 protini za damu zinazotumika kujenga anwani ya tukio la protini (ProS) kwa kusimamia changamoto za CRC kutoka kwa tathmini ya fasi kwa fasi ya proteomi (mchezaji ya utambulisho) na tathmini ya hazina ya kuharibu kwa kawaida (mchezaji wa kuthibitisha).
       </title>
       <p>
        Anwani ya
        <italic>
         P
        </italic>
        -value iliyotolewa ili kujibu kwa mtazamo wa kawaida, na muda wa kuharibu (FDR) uliogunduliwa kusimamia majaribio mengi. Katika mchezaji wa kuthibitisha, majazo ya mstari yanayoweza kuchunguza ni majazo ya hazina ya kuharibu yanayotolewa, na mstari yanayoweza kuchunguza ni majazo ya 95% ya kuchukua kwa imani. Data za kuzingatia zinazotolewa kama faili ya Source Data. Log
        <sub>
         2
        </sub>
        FC ni Log
        <sub>
         2
        </sub>
        fold change, FDR ni muda wa kuharibu, HR ni hazina ya kuharibu, CI ni kuchukua kwa imani.
       </p>
      </caption>
      <graphic href="/ProjectMundo/MediaObjects/10X1038_s41467-024-52894-2/41467_2024_52894_Fig2_HTML.png" mime-subtype="PNG" specific-use="web"/>
     </fig>
    </p>
   </sec>
   <sec id="Sec5">
    <title>
     Uundaji na uhakikishaji wa model ya maonyesho
    </title>
    <p id="Par8">
     Model ya maambukizi yanayohusiana na QCancer-S, PRSs, na ProS yaliyehitajiwa katika UKBB, kwa kawaida. Katika kikundi cha kujifunza, C-statistics ya QCancer-S na QCancer-S (inayojumuisha maeneo ya jumuiya) ilikuwa 0.71 (95% CI: 0.66, 0.76), na kuna tofauti yanayohusu hisabati sana (
     <italic>
      P
     </italic>
     = 0.63) (Fig.
     <xref ref-type="fig" rid="Fig3">
      3a
     </xref>
     , Supplementary Data
     <xref ref-type="supplementary-material" rid="MOESM4">
      2
     </xref>
     ). Kwa ajili ya kujitegemea, QCancer-S iliyotumika katika uundaji wa maambukizi yanayofuata na maanalizi. C-statistics ya ProS ilikuwa 0.66 (95% CI: 0.61, 0.71) (Fig.
     <xref ref-type="fig" rid="Fig3">
      3a
     </xref>
     ). Kati ya modele za PRS 2, LDpred2-grid ilifanya kazi vizuri zaidi, na C-statistic ya 0.74 (95% CI: 0.69, 0.80) (Supplementary Data
     <xref ref-type="supplementary-material" rid="MOESM4">
      2
     </xref>
     ). Kisha PRS (LDpred2-grid) yanayofanya kazi vizuri zaidi iliyotumika pamoja na QCancer-S na ProS ili uundwe model ya pamoja, na C-statistic ilipanda hadi 0.79 (95% CI: 0.75, 0.84), ambayo ilikuwa na tofauti yanayohusu hisabati sana kuliko model ya QCancer-S pekee katika kikundi cha kujifunza (C-statistic: 0.79 vs. 0.71,
     <italic>
      P
     </italic>
     = 4.94E–03) na kikundi cha kuthibitisha (C-statistic: 0.75 vs 0.69,
     <italic>
      P
     </italic>
     = 5.49E–04) (Fig.
     <xref ref-type="fig" rid="Fig3">
      3a
     </xref>
     , Supplementary Data
     <xref ref-type="supplementary-material" rid="MOESM4">
      2
     </xref>
     ).
     <fig id="Fig3" position="float">
      <label>
       Fig. 3
      </label>
      <caption xml:lang="en">
       <title>
        Uhusiano wa vifaa vya maonyesho ya hatari ya QCancer-15 (QCancer-S), vya hatari ya polygenic (PRS), vya hatari ya protini (ProS), na vya Mfumo wa Umuhimu wa CRC.
       </title>
       <p>
        <bold>
         a
        </bold>
        Mawingo ya uhusiano wa ROC ya QCancer-S, PRS, ProS, na Mfumo wa Umuhimu wa CRC katika kikundi cha kujifunza.
        <bold>
         b
        </bold>
        Mawingo ya uhusiano wa mifumo miwili ya kujihusisha na uwezekano wa CRC katika kikundi cha kujifunza.
        <bold>
         c
        </bold>
        Tathmini ya mifumo ya uhusiano wa QCancer-S na Mfumo wa Umuhimu wa CRC katika kikundi cha kujifunza, iliyohesabiwa kwa muda wa kuzingatia ya kati (13.05 miaka). Msimbo wa nyekundu kwenye mawingo ya faida ya kutosha yanayonekana kuonyesha kutosha, na msimbo wa kijani yanayonekana kuonyesha kutosha kwa wote.
        <bold>
         d
        </bold>
        Nomogramu ya kujihusisha na uwezekano wa kukuwa na CRC kwa 5, 10, na 15 miaka kwa jamii yote. Data za chanzo zinapatikana kama faili ya Source Data.
       </p>
      </caption>
      <graphic href="/ProjectMundo/MediaObjects/10X1038_s41467-024-52894-2/41467_2024_52894_Fig3_HTML.png" mime-subtype="PNG" specific-use="web"/>
     </fig>
    </p>
    <p id="Par9">
     Matokeo ya maanalizi yanayohusiana na kuzingatia kwa kikundi zinazozungumza zinazotunjazwa katika Supplementary Data
     <xref ref-type="supplementary-material" rid="MOESM4">
      3
     </xref>
     <sup/>
     . Katika kikundi cha kujifunza, C-statistic ya model ya pamoja ilikuwa 0.76 (95% CI: 0.69, 0.83) kwa wanawake na 0.77 (95% CI: 0.70, 0.84) kwa wanaume. Wakati kuzingatia hatari ya CRC kwa kikundi cha kikolon na kikundi cha kirekto, C-statistic ya model ya pamoja ilipanda hadi 0.79 (95% CI: 0.74, 0.85) kwa kansa ya kikolon na 0.82 (95% CI: 0.73, 0.91) kwa kansa ya kirekto. Model ya pamoja ilikuwa inafanya kazi vizuri zaidi kuliko QCancer-S pekee bila kuzingatia kama wafanyikazi walikuwa tayari kuzingatia kansa ya mifupa au historia ya familia ya CRC. C-statistic ya model ya pamoja ilipanda hadi 0.79 (95% CI: 0.73, 0.85) kwa wafanyikazi bila kuzingatia, 0.79 (95% CI: 0.62, 0.95) kwa wafanyikazi waliozaliwa tayari kuzingatia kabla ya kujaliwa katika UKBB moja miaka na zaidi, na 0.91 (95% CI: 0.85, 0.98) kwa wafanyikazi walio na historia ya familia. Matokeo yanayohusiana na kikundi cha kuthibitisha zilikuwa na changamoto sawa. Kwa wafanyikazi bila historia ya familia ya CRC na bila kuzingatia, model ya pamoja iliyotumika bado ilikuwa na tofauti yanayohusu hisabati sana kuliko QCancer-S pekee katika kikundi cha kujifunza (C-statistic, 0.82 vs. 0.71,
     <italic>
      P
     </italic>
     &lt; 0.05) na kikundi cha kuthibitisha (C-statistic, 0.75 vs. 0.71,
     <italic>
      P
     </italic>
     &lt; 0.05). Mawingu ya uharibifu yanayotumika kuzingatia kuonyesha kwamba mada yanayotumika na mada yanayotumika yanakuwa na uhusiano mzuri (Fig.
     <xref ref-type="fig" rid="Fig3">
      3b
     </xref>
     , Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      2
     </xref>
     ).
    </p>
   </sec>
   <sec id="Sec6">
    <title>
     Faida ya model ya maonyesho
    </title>
    <p id="Par10"/>
   </sec>
   <sec id="Sec7">
    <title>
     Ushirikiano wa hatari ya CRC kati ya anwani za hatari
    </title>
    <p id="Par11">
     <fig id="Fig4" position="float">
      <label>
       Fig. 4
      </label>
      <caption xml:lang="en">
       <title>
        Uhusiano wa hatari na miaka ya kujifunza ya kutosha ya CRC katika jamii yote kulingana na vikundi vya hatari.
       </title>
       <p>
        Kaplan–Meier mawingo ya uhusiano wa hatari ya kukuwa na CRC kulingana na vikundi vya hatari kulingana na (
        <bold>
         a
        </bold>
        ) QCancer-S (log-rank
        <italic>
         p
        </italic>
        = 4.13E–54), (
        <bold>
         b
        </bold>
        ) hatari ya polygenic (PRS) (log-rank
        <italic>
         p
        </italic>
        = 3.98E–79), (
        <bold>
         c
        </bold>
        ) hatari ya protini (ProS) (log-rank
        <italic>
         p
        </italic>
        = 5.08E–40), na (
        <bold>
         d
        </bold>
        ) hatari ya umuhimu (ComS) (log-rank
        <italic>
         p
        </italic>
        = 1.82E–121). Bandi za umbala zinazoweza kuchunguza kuzingatia. Uhusiano wa hatari ya 10 miaka kulingana na miaka ya umri wa CRC kwa watu kulingana na vikundi vya hatari kulingana na (
        <bold>
         e
        </bold>
        ) PRS, (
        <bold>
         f
        </bold>
        ) ProS, na (
        <bold>
         g
        </bold>
        ) ComS. Msimbo wa umbali kwenye mawingo ya uhusiano wa hatari ya 10 miaka kulingana na miaka ya umri yanayonekana kuonyesha hatari ya umri 50 miaka (miaka ya kujifunza ya kutosha ya watu wenye hatari ya kawaida iliyotolewa na mafadhaiko ya sasa) kwa jamii yote. Data za chanzo zinapatikana kama faili ya Source Data.
       </p>
      </caption>
      <graphic href="/ProjectMundo/MediaObjects/10X1038_s41467-024-52894-2/41467_2024_52894_Fig4_HTML.png" mime-subtype="PNG" specific-use="web"/>
     </fig>
    </p>
   </sec>
   <sec id="Sec8">
    <title>
     Muda wa ukweli wa hatari ya CRC kati ya anwani za ushirikiano
    </title>
    <p id="Par12"/>
   </sec>
   <sec id="Sec9">
    <title>
     Muda wa ukweli wa kuanza kuchunguza CRC
    </title>
    <p id="Par13">
     Risiki kumalizika kwa miaka 10 iliyohesabiwa baada ya kufafanulia umri wa kuanza kuchukua mfumo wa kuchukua picha ya kifupi kwa watu wote wa majina tofauti ya risiki. Umri wa wafanyabiashara wenye PRS nyingi, wasio na PRS, au wenye PRS nyingi waliokuja kwa risiki kumalizika kwa CRC kwa miaka 10 sawa na risiki kati ya watu wengi kwa umri wa miaka 50 ilikuwa &gt;60, 53, na 41 miaka (Fig.
     <xref ref-type="fig" rid="Fig4">
      4e
     </xref>
     , Table
     <xref ref-type="table" rid="Tab2">
      2
     </xref>
     ). Umri wa wafanyabiashara wenye ProS nyingi, wasio na ProS, au wenye ProS nyingi waliokuja kwa risiki kumalizika kwa CRC kwa miaka 10 sawa na risiki kati ya watu wengi kwa umri wa miaka 50 ilikuwa 57, 47, na 46 miaka (Fig.
     <xref ref-type="fig" rid="Fig4">
      4f
     </xref>
     , Table
     <xref ref-type="table" rid="Tab2">
      2
     </xref>
     ). Wakati wa kujumlia ProS, PRS, na QCancer-S, umri wa wafanyabiashara wenye ComS nyingi, wasio na ComS, au wenye ComS nyingi waliokuja kwa risiki kumalizika kwa CRC kwa miaka 10 sawa na risiki kati ya watu wengi kwa umri wa miaka 50 ilikuwa &gt;60, 48, na &lt;40 miaka (Fig.
     <xref ref-type="fig" rid="Fig4">
      4g
     </xref>
     , Table
     <xref ref-type="table" rid="Tab2">
      2
     </xref>
     ). Matokeo mara nyingi pia iliyotolewa kwenye wafanyabiashara bila historia ya familia ya CRC na bila kuchukua picha ya kifupi (Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      7
     </xref>
     , Supplementary Data
     <xref ref-type="supplementary-material" rid="MOESM4">
      7
     </xref>
     ).
    </p>
   </sec>
  </sec>
  <sec id="Sec10" sec-type="discussion">
   <title>
    Mazungumzo
   </title>
   <p id="Par14">
    Kwa kutumia mfumo wa mawasiliano mawili, tuliambatana na mikakati ya proteomic zinazohusiana na CRC na kutengeneza 15 biomarka za protini kwa ajili ya kusambaza risiki. Namaendeleo ya mfumo wa kuhakikisha ambao unajumlia mikakati ya proteomic na jinsi ya genetiki (i.e., PRS) na jinsi la si genetiki (i.e., QCancer-15) ilifanya zaidi vizuri kwa kila metriki kuliko QCancer-15 pekee. Pia, mfumo wa kujumlia ulikuwa na athari kubwa kwa kusambaza risiki ya kuanza ya CRC na kuhakikisha umri wa kuanza ya kuchukua picha ya kifupi ya CRC kulingana na risiki. Kulingana na kundi la risiki la kati, wafanyabiashara wenye ProS nyingi, PRS nyingi, au ComS nyingi walikuja kwa risiki sawa ya CRC kwa miaka 4.7, 17.9, au hata 27.5 zaidi, wakati wafanyabiashara wenye ProS chache, PRS chache, au ComS chache walikuja kwa risiki sawa ya CRC kwa miaka 4.4, 8.9 au 15.2 zaidi. Kulingana na watu wengi wanao umri wa miaka 50, wafanyabiashara wenye ProS nyingi, PRS nyingi, au ComS nyingi ilikuwa inatambulisha kuanza kuchukua picha ya kifupi kwa umri wa miaka 46, 41, au kabla ya 40, wakati kundi zilizo na anwani zaidi zilikuwa inatambulisha kuanza kuchukua picha ya kifupi kwa umri wa miaka 57 au baada ya 60. Matokeo mara nyingi pia iliyotolewa kwenye wafanyabiashara bila historia ya familia ya CRC na bila kuchukua picha ya kifupi.
   </p>
   <p id="Par15"/>
   <p id="Par16"/>
   <p id="Par17"/>
   <p id="Par18">
    Uchanganuzi huu una uwezo wengi. Kwanza, mwelekeo wa mwisho wa mawasiliano mbili uliondozwa kulingana na teknolojia za proteomika ya kasi ya juu ili kutambua maandishi ya proteomika yanayohusiana na CRC, ambayo aliathibitisha kuwa protini zinazo uhusiano wa kawaida na CRC kati ya jamii mbalimbali na mawasiliano ya proteomika zinatumika kwa uundaji, huku zilipanda uwezo wa kujulikana wa mafundisho haya. Pili, jamii ya mtaani ya maelezo ya mbele yenye namba ya sampuli kubwa, wakati wa kujifunza mzuri, na kufuata kwa muda mrefu aliweka ni mwenye uwezo wa kujenga mdoeli ya maelezo ya jamii ya kujitokeza kwa CRC. Tatu, kujenga mawasiliano ya proteomika yanayohusiana na mafunzo ya kijamii na mafunzo ya kijamii yanayohusiana na kigeni yanayotoa tafsiri ya kijamii ya hali za afya za binadamu, ambayo yaliathibitisha kwa uhusiano wa kawaida na kwa ujumla wa kuzingatia hatari ya CRC ili kusaidia kuzungumza zaidi ya nyaraka kwenye watu wenye hatari ya juu. Nne, RAP na hatari ya kumalizika kwa miaka 10 yalipatikana matokeo ya kawaida kwa ujumla wa miaka za kujifunza ya kujitokeza kwa CRC, ambayo iliyatoa maana ya uwakilishaji na uaminifu wa mafundisho ya sasa. Pia, viwango vilivyohitajiwa kwa uundaji wa mdoeli yanaweza kupatikana kutoka kwa maonyesho yanayohifadhiwa na kwa sampuli ya kisayansi moja yanayohakikishwa (i.e., damu), ambayo yanaweza kuhakikisha uwezo wa kujengwa na kupokea. Hata hivyo, viwango vingine vya uchanganuzi huu vinahitaji kujisikiliza kwa makini. Kwanza, bila kuwa na mafunzo yanayohusiana na CRC yanayotambuliwa kwa mwelekeo wa mawasiliano mbili yanayotumika kwa jamii ya Kiwae na UKBB, mdoeli ya maelezo yaliundwa katika UKBB (yanayohusu watu wa kigeni na wasio na kigeni) yenye uwezo wa kujisikiliza kwa ndani tu. Uchanganuzi wa zaidi uliondozwa kwenye jamii za nje za zaidi yanahitaji ili kujaribu uwezo wa kujulikana kabla ya kujifunza mafundisho haya katika huduma za marufuku. Pili, RAP na hatari ya kumalizika kwa miaka 10 haitumika katika kujaribu miaka ya kujifunza ya kujitokeza kwa CRC kwa mawasiliano mbalimbali ya QCancer-S kwa sababu ya nyaraka yenyewe inayohusiana na QCancer-S. Uchanganuzi wa zaidi kujaribu kuzingatia ya mafunzo yanayohusiana na kijamii yanayohusiana na kigeni (yanayofuata nyaraka) katika miaka ya kujifunza ya kujitokeza kwa CRC inaweza kuwa chenja. Pia, bila kuwa na viwango vya RAP vya kawaida kati ya mtaa wa kujifunza na mtaa wa kujaribu, viwango vya RAP vya mawasiliano vya hatari vya kadhaa hawalinipatikana maana katika mtaa wa kujaribu, ambavyo inaweza kuwa kwa sehemu moja ya sababu ya namba ya mawasiliano ya kidogo. Mwishowe, si tu miaka ya kujifunza ya kwanza tu ambayo yanayojumuisha lakini pia muda wa kujifunza yanayojumuisha katika mchakato wa kujifunza. Muda wa kujifunza ya kujitokeza kwa CRC yanayojumuisha yanahitaji kujaribu kwa uchanganuzi wa zaidi.
   </p>
   <p id="Par19">
    Kwa kawaida, kujenga mawasiliano ya damu proteomika na PRS na QCancer-15 yaliweka ni yaliyopanda uwezo wa kuzingatia na maana ya kliniki ya kujitokeza kwa miaka ya kujifunza ya kujitokeza kwa CRC. Hii inaweza kusaidia katika mchakato wa kufanya maamuzi kwa CRC, na ina uwezo wa kurekebisha nyaraka ya kujifunza ya watu wenye hatari ya chini, huku inapanda daraja ya kujifunza ya kujifunza. Uchanganuzi wa zaidi kujaribu kupokea, uwezo wa kujengwa, na uwezo wa kujitahidi kwa mdoeli ya kujenga na miaka ya kujifunza ya kujitokeza inahitaji.
   </p>
  </sec>
  <sec id="Sec11" sec-type="methods">
   <title>
    Ujuzi
   </title>
   <sec id="Sec12">
    <title>
     Matumaini ya matumaini na rukundo wa watu
    </title>
    <p id="Par20">
     Ruhusa ya kuzingatia kwa mtaa wa kujifunza wa hii uliondozwa kutoka kwa Viongozi wa Kuzingatia wa Hospitali ya Pili ya Chuo Kikuu cha Sayansi za Zhejiang (2023-1190). UKBB iliondozwa na North West Multicenter Research Ethics Committee (11/NW/0382). Wafanyikazi wote walipatikana ruhusa ya kuzingatia ya kushiriki, na uchanganuzi huu ulifanyika kulingana na Ujumbe wa Helsinki.
    </p>
   </sec>
   <sec id="Sec13">
    <title>
     Uzoefu wa uchunguzi na wakulima
    </title>
    <p id="Par21"/>
    <p id="Par22"/>
   </sec>
   <sec id="Sec14">
    <title>
     Uambatishaji wa matokeo
    </title>
    <p id="Par23">
     Matokeo muhimu ilikuwa ushujaa wa CRC, iliyoelezwa kama neoplasima za kibaya za kifupi na kirekati, iliyotathminiwa na klinician na pathologist katika kikundi cha ujulishaji, au kwa kutumia takwimu ya Ailmenti za Kibinadamu (ICD, ICD-9: 153, 154.0, 154.1; au ICD-10: C18-C20) katika UKBB kwa njia ya usambazaji na data za hospitali na serekali za ushujaa na kifo. Tarehe ya kujisajili kwa mshiriki katika UKBB ilifanyika kama mwanafunzi wa muda wa kufuata, na kufuata ilikufungwa tarehe ya ujulishaji wa CRC, kifo, kufuata, au mwisho wa kufuata kwa serekali (March 31, 2021), yoyote yoyote ya zile zilizotokea kwanza.
    </p>
   </sec>
   <sec id="Sec15">
    <title>
     Ukurasa proteomu ya damu
    </title>
    <p id="Par24">
     Vifurushi vilikuwa vinavyotolewa kutoka kwa wafanyikazi wakati wa kujisajili, na sampuli za plasma zilikuwa zinatengenezwa na zinahifadhiwa kwenye –80 °C. Ukurasa wa protini zilikuwa zinatengenezwa kwa kutumia iodo Tandem Mass Tags (TMT)-6plex quantitative proteomics katika kikundi cha ujulishaji. Segmenzi za peptidi zilikuwa zinatengenezwa kwa nisaba ya kanali za sampuli za CRC kwa kanali za kikundi cha kawaida na zilikuwa zinatathminiwa kwa Log
     <sub>
      2
     </sub>
     na zinatengenezwa kwa njia ya quantiles. Maelezo ya ukurasa wa protini, usasishaji, na uongozi wa ubora (QC) yameelezwa katika Supplementary Methods. Baada ya QC, jumla ya 606 protini zilikuwa zimeanuliwa na zilikuwa zimejumuisha katika maanalizi yanayofuata (Supplementary Data
     <xref ref-type="supplementary-material" rid="MOESM4">
      8
     </xref>
     ).
    </p>
    <p id="Par25">
     Katika UKBB, maelezo ya chaguo la sampuli, ukurasa wa protini, usasishaji, na uongozi wa ubora (QC) yameelezwa nje
     <sup>
      <xref ref-type="bibr" rid="CR28">
       28
      </xref>
     </sup>
     . Kwa njia ya kwa kwa, ubora wa 2923 protini ulikuwa umeanuliwa kwa kutumia Olink Proximity Extension Assay, na ukurasa zilikuwa zinatolewa kama thamani za ubora za protini zinazotathminiwa kwa Log
     <sub>
      2
     </sub>
     . Thamani za protini zinazojaa chini ya nyingineo ya kuzungumzwa (LOD) zilikuwa zinabadilika kwa kuzingatia LOD kwa kihisi ya 2. Ukurasa zinazofikia kwa protini zilikuwa zinatengenezwa kwa thamani za moyo. Kwa protini zinazojaa kati ya mawasiliano ya CRC na kawaida katika mada ya ujulishaji, tulikuwa tumevya maelezo zao na ujulishaji wa CRC kulingana na mada ya kikundi cha kifurudhi katika UKBB.
    </p>
   </sec>
   <sec id="Sec16">
    <title>
     Uchanganuzi wa tiba
    </title>
    <sec id="Sec17">
     <title>
      Maelezo ya sifa za asili
     </title>
     <p id="Par26">
      Tuzo la Kolmogorov–Smirnov la normaliti ya kawaida iliyotumika kutoa aina za tofauti za variable za kina. Median (IQR) iliyotumika kutoa variable za kina, na namba (nisaba) iliyotumika kutoa variable za kikundi.
     </p>
    </sec>
   </sec>
   <sec id="Sec18">
    <title>
     Uambatishaji wa alama za proteomu za CRC
    </title>
    <p id="Par27">
     Taktiki ya mada mbili iliyotumika kutoa alama za protini zinazohusiana na CRC. Katika mada ya ujulishaji kulingana na mada ya kawaida, taktiki ya mawasiliano na tuzo la Pearson correlation coefficient matrix iliyotumika kutoa sampuli za outlier (Supplementary Methods), na 20 sampuli zinazojaa tofauti kwa kina zilikuwa zimeanuliwa (Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      8
     </xref>
     ). Baada ya kusindikiza sampuli za outlier, ukurasa wa protini wa kina kwa kina kulingana na ‘limma’ package iliyotumika kutoa protini zinazojaa kujadili (Log
     <sub>
      2
     </sub>
     FC &gt; 0) au kujadili (Log
     <sub>
      2
     </sub>
     FC &lt; 0) kati ya mawasiliano ya CRC na kawaida. FDR iliyotumika kusambaza tofauti nyingi, na FDR &lt; 0.05 iliyotumika kama nivo ya maana. Kwa protini zinazojaa maana (FDR &lt; 0.05) katika mada ya ujulishaji, tulikuwa tumevya maelezo zao kwa kutumia modele za Cox proportional hazards (CPH) kutoa maelezo yao na ujulishaji wa CRC katika kikundi cha kifurudhi. Protini yenye maelezo ya kina na thamani ya
     <italic>
      P
     </italic>
     -value (
     <italic>
      P
     </italic>
     &lt; 0.05) katika mada ya kifurudhi iliyotumika kama tofauti ya kina
     <sup>
      <xref ref-type="bibr" rid="CR29">
       29
      </xref>
     </sup>
     .
    </p>
   </sec>
   <sec id="Sec19">
    <title>
     Uambatishaji wa QCancer-15
    </title>
    <p id="Par28">
     Mazungumzo ya QCancer-15 yalikuwa yameandaliwa kulingana na sifa za awali za UKBB zinazokumbukizwa kwa urahisi kama model ya kwanza
     <sup>
      <xref ref-type="bibr" rid="CR11">
       11
      </xref>
      ,
      <xref ref-type="bibr" rid="CR12">
       12
      </xref>
     </sup>
     . Mazungumzo ya QCancer-15 yalinikwa miaka (miaka kwa wakati wa kujisajili), jinsia, indeksi ya Townsend ya ukunjwa, eneo la jumuiya, indeksi ya uzito (BMI), hali ya kusisimua sigara, kumaliza nyama, historia ya familia ya CRC, na historia ya afya ya kuzidi. Wafanyabiashara ambao walikuwa na data yanayofikia katika mazungumzo haya zilipatikana katika kundi la “Hakuna Data” kwa kila mazungumzo. Maelezo ya andishi ya mazungumzo haya zinazostahili yanavyonyozi katika Data ya Kusaidia
     <xref ref-type="supplementary-material" rid="MOESM4">
      9
     </xref>
     <sup/>
     . Kwa ajili ya kujitegemea katika jumuiya nyingine, tulitokomea mazungumzo ya eneo la jumuiya ambayo ilikuwa imetengenezwa kulingana na jumuiya ya UK kutoka kwa mazungumzo ya QCancer-15.
    </p>
   </sec>
   <sec id="Sec20">
    <title>
     Ujuzi wa anwani ya hatari polygeni (PRS)
    </title>
    <p id="Par29">
     Matafsiri ya CRC ya kubwa zaidi ya kila nchi (21,731 matukio na 47,444 wakaribana wa asili ya Asia Mashariki; 78,473 matukio na 107,143 wakaribana wa asili ya Ulaya) iliyotumika ili kutoa ukubwa wa athari ya uhusiano wa kila SNP. LDpred2 ilitumika ili kujenga PRS ya genome kwa ujumla, ambayo inabinafsia kwa uamuzi wa Bayesian na huambatana na ukuaji wa uhusiano (LD) kati ya SNP
     <sup>
      <xref ref-type="bibr" rid="CR30">
       30
      </xref>
      <xref ref-type="bibr" rid="CR31">
       31
      </xref>
     </sup>
     . Vitengenezaji viwili vya LDpred2 vilivyotumika, vilivyohusu model ya auto (LDpred2-auto) na model ya grid (LDpred2-grid), kwa kutumia dataset ya HapMap3+ kama maelezo. Jumla ya 2 PRS zilizotengenezwa. Maelezo yanavyonyozi yanavyonyozi katika Supplementary Methods.
    </p>
   </sec>
   <sec id="Sec21">
    <title>
     Uundaji wa anwani za hatari na uundaji wa model ya maonyesho
    </title>
    <p id="Par30"/>
   </sec>
   <sec id="Sec22">
    <title>
     Uhakikishaji ya ujuzi wa model na fayda ya kliniki
    </title>
    <p id="Par31"/>
   </sec>
   <sec id="Sec23">
    <title>
     Ujuzi na uharibika wa model
    </title>
    <p id="Par32"/>
   </sec>
   <sec id="Sec24">
    <title>
     Uchanganuzi wa mstari wa fayda
    </title>
    <p id="Par33">
     Kuambatana na umuhimu wa kliniki wa vifaa vya maonyesho kwa uambukuzi wa CRC (kumbuka, screening), tathmini ya mstari wa kuchukua ushuru (decision curve analysis) ilifanyika kwa kutumia ‘ggDCA’ package ili kuhesabi faida neti (NB) iliyopatikana kwa kutumia QCancer-S peke yake au modeli ya pamoja (QCancer-S + PRS + ProS) ili kuchagua watu kwa screening colonoscopy. NB = ((true positives)/
     <italic>
      n
     </italic>
     ) – ((false positives)/
     <italic>
      n
     </italic>
     ) ∗ (
     <italic>
      P
     </italic>
     <sub>
      t
     </sub>
     /(1−
     <italic>
      P
     </italic>
     <sub>
      t
     </sub>
     )), ambapo
     <italic>
      n
     </italic>
     ni jumla ya watu, na
     <italic>
      P
     </italic>
     <sub>
      t
     </sub>
     ni hatari (au umahakikiano) threshold (kumbuka,
     <italic>
      P
     </italic>
     <sub>
      t
     </sub>
     = 1%, ni ni wazi kufanya colonoscopy kwa 100 watu kusoma moja ya CRC)
     <sup>
      <xref ref-type="bibr" rid="CR34">
       34
      </xref>
      <xref ref-type="bibr" rid="CR34">
       34
      </xref>
     </sup>
     . Tuliyasembenyisha modeli ya pamoja na modeli ya kulingana na QCancer-S peke yake, kama vile kufanya ushuru kwa hakuna na kufanya ushuru kwa wote. Uongezi wa namba ya false positives kwa kila 100 watu iliyohesabiwa kwa formula: 100*(NB ya modeli–NB ya ushuru wote)/(
     <italic>
      P
     </italic>
     <sub>
      t
     </sub>
     /(1–
     <italic>
      P
     </italic>
     <sub>
      t
     </sub>
     )). NBs kwa hatari za threshold zinazohusiana zilipatikana kwenye mstari ya kuchukua ushuru kwa muda wa kufuata kati (13.05 miaka). Thamani za NB kwa hatari za threshold zinazohusiana (1%, 1.5%, 2%, 2.5%, na 3%) zilipatikana.
    </p>
   </sec>
   <sec id="Sec25">
    <title>
     Ugunduzi wa nisabu za hatari na uchanganuzi wa ushirikiano
    </title>
    <p id="Par34">
     HRs iliyopatikana kwanza kutoka kwa CPH regression kwa kila SD ya ukubwa katika QCancer-S, PRS, na ProS kwa jumla, kwa jinsia, na kwa mahali ya CRC. Baadaye, QCancer-S, PRS, ProS, na ComS (Supplementary Methods) iligawanyika kwa quartiles (Q1-lowest, Q2, Q3, na Q4-highest) kulingana na utambulisho wao katika UKBB ya sasa, kwa kila moja. Kwa sababu ya mchanganyiko sawa katika mstari ya 10 miaka ya hatari ya kumalizika, hatari za usimamizi ziligeuza kwa 3 vikundi (low, medium, na high) (Supplementary Fig.
     <xref ref-type="supplementary-material" rid="MOESM1">
      9
     </xref>
     ). Kwa kujelisishia, kwa kutumia 10 miaka ya hatari ya kumalizika kwenye jumla ya watu kama mfano, watu katika Q3 wenye hatari sawa na jumla ya watu waligeuza kwa vikundi vya hatari vya kati, watu katika Q1 na Q2 wenye hatari chache zaidi kuliko jumla ya watu waligeuza kwa vikundi vya hatari vya chache, na watu katika Q4 waligeuza kwa vikundi vya hatari vya juu. HRs (95% CIs) pia iliyohesabiwa kwa athi za kategoria kwa kutumia vikundi vya kati kama mfano. Thamani ya usimamizi wa hatari za usimamizi iliyohakikishwa kwa mstari ya Kaplan–Meier na tuzo za log-rank.
    </p>
   </sec>
   <sec id="Sec26">
    <title>
     Uchanganuzi wa muda wa ukweli wa hatari (RAP)
    </title>
    <p id="Par35">
     Kuambatana na HRs ya PRS, ProS, na ComS kwa miaka ya umri zinazofuata au zinazosimama kwa watu katika vikundi vya chache au juu ya PRS, ProS, na ComS zilipatikana kwa hatari zinazosawa na mfano (i.e., wale katika PRS, ProS, au ComS ya kati), tathmini ya RAP ilifanyika. QCancer-S iliyotokana na RAP kwa sababu ya taarifa za umri iliyohusiana na kuzingatia katika QCancer-S. Thamani za RAPs iliyopatikana kwa tathmini ya CPH modeli ya kawaida zaidi, iliyojumuisha umri, PRS (chache, kati, juu), na ProS (chache, kati, juu), na jinsia na 10 kawaida za kwanza za majimbo ya geneti (PCs) kama athi, kwa kuzingatia thamani ya regression ya PRS au ProS kwa thamani ya regression ya umri. Wakati wa kuhesabi RAP ya ComS, modeli iliyojumuisha umri, ComS (chache, kati, juu), jinsia, na 10 PCs, kwa ambayo RAP iliyohesabiwa kwa kuzingatia thamani ya regression ya ComS kwa thamani ya regression ya umri. 95% CIs ya RAPs iliyohesabiwa kulingana na bootstrap method, kwa 500 bootstrap replicates
     <sup>
      <xref ref-type="bibr" rid="CR35">
       35
      </xref>
     </sup>
     .
    </p>
   </sec>
   <sec id="Sec27">
    <title>
     Ugunduzi wa muda wa ukweli wa kuanza kuchunguza
    </title>
    <p id="Par36">
     Kwa kujulikisha zaidi umri wa kuanza ya screening kwa watu wa vikundi vya hatari mbalimbali, 10 miaka ya hatari ya kumalizika iliyohesabiwa. Kukumbuka kuwa jumla ya UKBB ya sasa ni zaidi ya kujulikisha na kutoa umri wa kuanza ya screening kulingana na jumla ya watu, tukuhesabi umri wa kuanza ya screening kulingana na jumla ya watu. 10 miaka ya hatari ya kumalizika = 1–exp(–10 miaka ya hatari ya kumalizika), ambapo 10 miaka ya hatari ya kumalizika iliyosawa na jumla ya miaka ya hatari ya kumalizika ya kila umri kulingana na miaka ya kila umri
     <sup>
      <xref ref-type="bibr" rid="CR36">
       36
      </xref>
     </sup>
     . Hatari ya kumalizika ya kila umri ya kila umri iliyohesabiwa kwa kuzingatia namba ya matukio kwa kila umri kwa miaka ya kila umri. Kukumbuka kuwa umri wa kuanza ya screening ni 50 miaka kwa watu wa hatari ya kati ambayo marafiki ya sasa yanarekebisha, tukuhesabi umri wa kuanza ya screening kulingana na jumla ya watu kama umri ambapo watu wenye hatari fulani ya CRC walipata hatari ya kumalizika ya 10 miaka sawa na jumla ya watu wa 50 miaka
     <sup>
      <xref ref-type="bibr" rid="CR27">
       27
      </xref>
      <xref ref-type="bibr" rid="CR36">
       36
      </xref>
     </sup>
     . Zote za majaribio iliyotathmini zilifanyika kwa upya na zilifanyika kwa kutumia R version 4.2.2.
    </p>
   </sec>
   <sec id="Sec28">
    <title>
     Ujumla wa ulazimisho
    </title>
    <p id="Par37">
     Taarifa zaidi kuhusu mifano ya utafiti yamepatikana kwenye
     <xref ref-type="supplementary-material" rid="MOESM5">
      Nature Portfolio Reporting Summary
     </xref>
     uliyolinkwa kwenye makala hii.
    </p>
   </sec>
  </sec>
 </body>
 <back>
  <ack>
   <title>
    Acknowledgements
   </title>
   <p>
    Waziri wamefurahia wachezaji wote kutoka kwa Hospitali ya Pili ya Chuo Kikuu cha Zhejiang University na UK Biobank, mashirika na wafanyiji wao kwa kutoa data. Q.X. anasaidiawa na National Natural Science Foundation of China (No. 82072360, 82373234) na Project of the regional diagnosis and treatment center of the Health Planning Committee (No. JBZX-201903). X.L. anasaidiawa na Natural Science Fund for Distinguished Young Scholars of Zhejiang Province (LR22H260001), National Nature Science Foundation of China (82204019), na Zhejiang Provincial Clinical Research Center for CANCER (2022E50008, 2024ZY01056). Y.H. anasaidiawa na Zhejiang Province Clinical Research Center for CANCER (2022E50008.2024ZY01056) na Key R&amp;D Program of Zhejiang (2023C03049). Wafanyiji waliofanya kazi hawakuwa na kigeni katika mchakato wa uundaji wa uchunguzi, ujumbe wa data na uanalizi, ukweli kuanza kutoa, au uandaji wa manuskrip.
   </p>
  </ack>
  <sec sec-type="author-contribution">
   <title>
    Author contributions
   </title>
   <p>
    Waziri hawa ni waziri wanaotambuliwa kwa kawaida: Xue Li, Qian Xiao, Junli Gao. X.L., Q.X., J.-L.G., na J.S. wamehusika katika uundaji na uchakato wa uchunguzi. Uvumilishaji wa data, ujumbe wa data, uchanganuzi, uanalizi rasmi, na uonyeshaji ulifanyika na J.S., Y.L., J.Z., B.L., na S.Z. H.G., J.-S.G., W.L., J.W., Y.-T.H., na X.K. wamehusika katika uhusiano wa projekti. Manuskrip ya kwanza ya kutoa yaliandaliwa na J.S., X.L., Q.X., J-L.G. na waziri wengine wote wameandaa na kumalizia manuskrip za zile zilizoenda. X.L. ni waziri wa kawaida wa uchunguzi na anasaidia kuwa waziri wote wamepewa maana ya kuzingatia na wanaokosa wengine wanaopewa maana. Waziri wote wamekutana na kusubiri manuskrip ya mwisho.
   </p>
  </sec>
  <sec sec-type="peer-review">
   <title>
    Uthibitishaji wa wanaomuathiri
   </title>
   <sec id="FPar1">
    <title>
     Uthibitishaji wa wanaomuathiri
    </title>
    <p id="Par38">
     <italic>
      Nature Communications
     </italic>
     thanks Jun Zhong and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. A peer review file is available.
    </p>
   </sec>
  </sec>
  <sec sec-type="data-availability">
   <title>
    Uvumilivu wa data
   </title>
   <p>
    The raw data of plasma proteomics generated in this study have been deposited in the iProX database under accession code IPX0008947000 (the equivalent ProteomeXChange PXD code: PXD054569) and
    <ext-link ext-link-type="uri" xlink:href="https://www.iprox.cn//page/subproject.html?id=IPX0008947001">
     IPX0008947001
    </ext-link>
    . The UK Biobank data are available under restricted access for data protocol, access can be obtained by registering and applying at
    <ext-link ext-link-type="uri" xlink:href="http://ukbiobank.ac.uk/register-apply/">
     http://ukbiobank.ac.uk/register-apply/
    </ext-link>
    . This study used the UK Biobank data under application number 66354. The result data generated in this study are provided in the Supplementary Information/Source Data file. The CRC GWAS summary statistics
    <sup>
     <xref ref-type="bibr" rid="CR30">
      30
     </xref>
    </sup>
    are available through the GWAS catalog (accession no. GCST90129505).
    <xref ref-type="sec" rid="Sec30">
     Source data
    </xref>
    are provided with this paper.
   </p>
  </sec>
  <sec sec-type="data-availability">
   <title>
    Uvumilivu wa programu
   </title>
   <p>
    Analysis code is available at
    <ext-link ext-link-type="uri" xlink:href="https://github.com/shuaidexue/Proteomics-predicted-colorectal-cancer-risk">
     https://github.com/shuaidexue/Proteomics-predicted-colorectal-cancer-risk
    </ext-link>
    .
   </p>
  </sec>
  <sec sec-type="ethics-statement">
   <sec id="FPar2" sec-type="COI-statement">
    <title>
     Masharti ya uchukuli
    </title>
    <p id="Par39">
     The authors declare no competing interests.
    </p>
   </sec>
  </sec>
  <ref-list id="Bib1">
   <title>
    Viungo vya kujadili
   </title>
   <ref-list>
    <ref id="CR1">
     <label>
      1.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Sung
        </surname>
        <given-names>
         H
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
      </article-title>
      <source>
       CA Cancer J. Clin.
      </source>
      <year>
       2021
      </year>
      <volume>
       71
      </volume>
      <fpage>
       209
      </fpage>
      <lpage>
       249
      </lpage>
      <pub-id pub-id-type="doi">
       10.3322/caac.21660
      </pub-id>
      <pub-id pub-id-type="pmid">
       33538338
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR2">
     <label>
      2.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Sinicrope
        </surname>
        <given-names>
         FA
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Increasing incidence of early-onset colorectal cancer
      </article-title>
      <source>
       N. Engl. J. Med.
      </source>
      <year>
       2022
      </year>
      <volume>
       386
      </volume>
      <fpage>
       1547
      </fpage>
      <lpage>
       1558
      </lpage>
      <pub-id pub-id-type="doi">
       10.1056/NEJMra2200869
      </pub-id>
      <pub-id pub-id-type="pmid">
       35443109
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38XhtFGrsLnM
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR3">
     <label>
      3.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Anderson
        </surname>
        <given-names>
         NL
        </given-names>
       </name>
       <name>
        <surname>
         Anderson
        </surname>
        <given-names>
         NG
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       The human plasma proteome: history, character, and diagnostic prospects
      </article-title>
      <source>
       Mol. Cell Proteom.
      </source>
      <year>
       2002
      </year>
      <volume>
       1
      </volume>
      <fpage>
       845
      </fpage>
      <lpage>
       867
      </lpage>
      <pub-id pub-id-type="doi">
       10.1074/mcp.R200007-MCP200
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BD3sXht1Ciug%3D%3D
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR4">
     <label>
      4.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Suhre
        </surname>
        <given-names>
         K
        </given-names>
       </name>
       <name>
        <surname>
         McCarthy
        </surname>
        <given-names>
         MI
        </given-names>
       </name>
       <name>
        <surname>
         Schwenk
        </surname>
        <given-names>
         JM
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Genetics meets proteomics: perspectives for large population-based studies
      </article-title>
      <source>
       Nat. Rev. Genet.
      </source>
      <year>
       2021
      </year>
      <volume>
       22
      </volume>
      <fpage>
       19
      </fpage>
      <lpage>
       37
      </lpage>
      <pub-id pub-id-type="doi">
       10.1038/s41576-020-0268-2
      </pub-id>
      <pub-id pub-id-type="pmid">
       32860016
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3cXhslSltLnL
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR5">
     <label>
      5.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Sun
        </surname>
        <given-names>
         J
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Identification of novel protein biomarkers and drug targets for colorectal cancer by integrating human plasma proteome with genome
      </article-title>
      <source>
       Genome Med.
      </source>
      <year>
       2023
      </year>
      <volume>
       15
      </volume>
      <pub-id pub-id-type="doi">
       10.1186/s13073-023-01229-9
      </pub-id>
      <pub-id pub-id-type="pmid">
       37726845
      </pub-id>
      <pub-id pub-id-type="pmcid">
       10508028
      </pub-id>
      <elocation-id>
       75
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR6">
     <label>
      6.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Sun
        </surname>
        <given-names>
         X
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Prospective
      </article-title>
      <source>
       Cancers
      </source>
      <year>
       2022
      </year>
      <volume>
       14
      </volume>
      <fpage>
       3261
      </fpage>
      <pub-id pub-id-type="doi">
       10.3390/cancers14133261
      </pub-id>
      <pub-id pub-id-type="pmid">
       35805033
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9265260
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38XhvVCltrrP
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR7">
     <label>
      7.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Ahn
        </surname>
        <given-names>
         SB
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Potential early clinical stage colorectal cancer diagnosis using a proteomics blood test panel
      </article-title>
      <source>
       Clin. Proteom.
      </source>
      <year>
       2019
      </year>
      <volume>
       16
      </volume>
      <fpage>
       34
      </fpage>
      <pub-id pub-id-type="doi">
       10.1186/s12014-019-9255-z
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR8">
     <label>
      8.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Harlid
        </surname>
        <given-names>
         S
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       A two-tiered targeted proteomics approach to identify pre-diagnostic biomarkers of colorectal cancer risk
      </article-title>
      <source>
       Sci. Rep.
      </source>
      <year>
       2021
      </year>
      <volume>
       11
      </volume>
      <pub-id assigning-authority="NASA Astrophysics Data System" pub-id-type="other">
       2021NatSR..11.5151H
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41598-021-83968-6
      </pub-id>
      <pub-id pub-id-type="pmid">
       33664295
      </pub-id>
      <pub-id pub-id-type="pmcid">
       7933352
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3MXlvF2htbw%3D
      </pub-id>
      <elocation-id>
       5151
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR9">
     <label>
      9.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Fang
        </surname>
        <given-names>
         Z
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Risk prediction models for colorectal cancer: evaluating the discrimination due to added biomarkers
      </article-title>
      <source>
       Int. J. Cancer
      </source>
      <year>
       2021
      </year>
      <volume>
       149
      </volume>
      <fpage>
       1021
      </fpage>
      <lpage>
       1030
      </lpage>
      <pub-id pub-id-type="doi">
       10.1002/ijc.33621
      </pub-id>
      <pub-id pub-id-type="pmid">
       33948940
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3MXhtFGksL7E
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR10">
     <label>
      10.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Usher-Smith
        </surname>
        <given-names>
         JA
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       External validation of risk prediction models for incident colorectal cancer using UK Biobank
      </article-title>
      <source>
       Br. J. Cancer
      </source>
      <year>
       2018
      </year>
      <volume>
       118
      </volume>
      <fpage>
       750
      </fpage>
      <lpage>
       759
      </lpage>
      <pub-id pub-id-type="doi">
       10.1038/bjc.2017.463
      </pub-id>
      <pub-id pub-id-type="pmid">
       29381683
      </pub-id>
      <pub-id pub-id-type="pmcid">
       5846069
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:STN:280:DC%2BC1MvlsVOhsQ%3D%3D
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR11">
     <label>
      11.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Hippisley-Cox
        </surname>
        <given-names>
         J
        </given-names>
       </name>
       <name>
        <surname>
         Coupland
        </surname>
        <given-names>
         C
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Development and validation of risk prediction algorithms to estimate future risk of common cancers in men and women: prospective cohort study
      </article-title>
      <source>
       BMJ Open
      </source>
      <year>
       2015
      </year>
      <volume>
       5
      </volume>
      <fpage>
       e007825
      </fpage>
      <pub-id pub-id-type="doi">
       10.1136/bmjopen-2015-007825
      </pub-id>
      <pub-id pub-id-type="pmid">
       25783428
      </pub-id>
      <pub-id pub-id-type="pmcid">
       4368998
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR12">
     <label>
      12.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Briggs
        </surname>
        <given-names>
         SEW
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Integrating genome-wide polygenic risk scores and non-genetic risk to predict colorectal cancer diagnosis using UK Biobank data: population based cohort study
      </article-title>
      <source>
       BMJ
      </source>
      <year>
       2022
      </year>
      <volume>
       379
      </volume>
      <fpage>
       e071707
      </fpage>
      <pub-id pub-id-type="doi">
       10.1136/bmj-2022-071707
      </pub-id>
      <pub-id pub-id-type="pmid">
       36351667
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9644277
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR13">
     <label>
      13.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Vocka
        </surname>
        <given-names>
         M
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Trefoil factor family (TFF) proteins as potential serum biomarkers in patients with metastatic colorectal cancer
      </article-title>
      <source>
       Neoplasma
      </source>
      <year>
       2015
      </year>
      <volume>
       62
      </volume>
      <fpage>
       470
      </fpage>
      <lpage>
       477
      </lpage>
      <pub-id pub-id-type="doi">
       10.4149/neo_2015_056
      </pub-id>
      <pub-id pub-id-type="pmid">
       25866228
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC28Xlt12hsbs%3D
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR14">
     <label>
      14.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Huang
        </surname>
        <given-names>
         Y
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       High expression of LTBP2 contributes to poor prognosis in colorectal cancer patients and correlates with the mesenchymal colorectal cancer subtype
      </article-title>
      <source>
       Dis. Mark.
      </source>
      <year>
       2019
      </year>
      <volume>
       2019
      </volume>
      <elocation-id>
       5231269
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR15">
     <label>
      15.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Wang
        </surname>
        <given-names>
         H
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Predictive value of proteomic markers for advanced rectal cancer with neoadjuvant chemoradiotherapy
      </article-title>
      <source>
       BMC Cancer
      </source>
      <year>
       2022
      </year>
      <volume>
       22
      </volume>
      <pub-id pub-id-type="doi">
       10.1186/s12885-022-09960-z
      </pub-id>
      <pub-id pub-id-type="pmid">
       35945555
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9361520
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38Xit1Cls7zI
      </pub-id>
      <elocation-id>
       868
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR16">
     <label>
      16.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Yusufu
        </surname>
        <given-names>
         A
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       TFF3 and TFF1 expression levels are elevated in colorectal cancer and promote the malignant behavior of colon cancer by activating the EMT process
      </article-title>
      <source>
       Int. J. Oncol.
      </source>
      <year>
       2019
      </year>
      <volume>
       55
      </volume>
      <fpage>
       789
      </fpage>
      <lpage>
       804
      </lpage>
      <pub-id pub-id-type="pmid">
       31432157
      </pub-id>
      <pub-id pub-id-type="pmcid">
       6741840
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3cXhsVCgsLs%3D
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR17">
     <label>
      17.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Shi
        </surname>
        <given-names>
         LP
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       MicroRNA-149 sensitizes colorectal cancer to radiotherapy by downregulating human epididymis protein 4
      </article-title>
      <source>
       Am. J. Cancer Res
      </source>
      <year>
       2018
      </year>
      <volume>
       8
      </volume>
      <fpage>
       30
      </fpage>
      <lpage>
       38
      </lpage>
      <pub-id pub-id-type="pmid">
       29416918
      </pub-id>
      <pub-id pub-id-type="pmcid">
       5794719
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC1MXntlyitro%3D
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR18">
     <label>
      18.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Delloye-Bourgeois
        </surname>
        <given-names>
         C
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Sonic Hedgehog promotes tumor cell survival by inhibiting CDON pro-apoptotic activity
      </article-title>
      <source>
       PLoS Biol.
      </source>
      <year>
       2013
      </year>
      <volume>
       11
      </volume>
      <fpage>
       e1001623
      </fpage>
      <pub-id pub-id-type="doi">
       10.1371/journal.pbio.1001623
      </pub-id>
      <pub-id pub-id-type="pmid">
       23940460
      </pub-id>
      <pub-id pub-id-type="pmcid">
       3735457
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR19">
     <label>
      19.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Baharudin
        </surname>
        <given-names>
         R
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Identification of predictive DNA methylation biomarkers for chemotherapy response in colorectal cancer
      </article-title>
      <source>
       Front Pharm.
      </source>
      <year>
       2017
      </year>
      <volume>
       8
      </volume>
      <fpage>
       47
      </fpage>
      <pub-id pub-id-type="doi">
       10.3389/fphar.2017.00047
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR20">
     <label>
      20.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Zhao
        </surname>
        <given-names>
         Q
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Comprehensive profiling of 1015 patients’ exomes reveals genomic-clinical associations in colorectal cancer
      </article-title>
      <source>
       Nat. Commun.
      </source>
      <year>
       2022
      </year>
      <volume>
       13
      </volume>
      <pub-id assigning-authority="NASA Astrophysics Data System" pub-id-type="other">
       2022NatCo..13.2342Z
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41467-022-30062-8
      </pub-id>
      <pub-id pub-id-type="pmid">
       35487942
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9055073
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38XhtFOhsb%2FE
      </pub-id>
      <elocation-id>
       2342
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR21">
     <label>
      21.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Fitzgerald
        </surname>
        <given-names>
         RC
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       The future of early cancer detection
      </article-title>
      <source>
       Nat. Med.
      </source>
      <year>
       2022
      </year>
      <volume>
       28
      </volume>
      <fpage>
       666
      </fpage>
      <lpage>
       677
      </lpage>
      <pub-id pub-id-type="doi">
       10.1038/s41591-022-01746-x
      </pub-id>
      <pub-id pub-id-type="pmid">
       35440720
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38XhtVGrsLbE
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR22">
     <label>
      22.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Thomas
        </surname>
        <given-names>
         M
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Combining Asian and European genome-wide association studies of colorectal cancer improves risk prediction across racial and ethnic populations
      </article-title>
      <source>
       Nat. Commun.
      </source>
      <year>
       2023
      </year>
      <volume>
       14
      </volume>
      <pub-id assigning-authority="NASA Astrophysics Data System" pub-id-type="other">
       2023NatCo..14.6147T
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41467-023-41819-0
      </pub-id>
      <pub-id pub-id-type="pmid">
       37783704
      </pub-id>
      <pub-id pub-id-type="pmcid">
       10545678
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3sXitVKlsbzE
      </pub-id>
      <elocation-id>
       6147
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR23">
     <label>
      23.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Li
        </surname>
        <given-names>
         X
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Prediction of colorectal cancer risk based on profiling with common genetic variants
      </article-title>
      <source>
       Int. J. Cancer
      </source>
      <year>
       2020
      </year>
      <volume>
       147
      </volume>
      <fpage>
       3431
      </fpage>
      <lpage>
       3437
      </lpage>
      <pub-id pub-id-type="doi">
       10.1002/ijc.33191
      </pub-id>
      <pub-id pub-id-type="pmid">
       32638365
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3cXhsVSrsLnM
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR24">
     <label>
      24.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Kachuri
        </surname>
        <given-names>
         L
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Pan-cancer analysis demonstrates that integrating polygenic risk scores with modifiable risk factors improves risk prediction
      </article-title>
      <source>
       Nat. Commun.
      </source>
      <year>
       2020
      </year>
      <volume>
       11
      </volume>
      <pub-id assigning-authority="NASA Astrophysics Data System" pub-id-type="other">
       2020NatCo..11.6084K
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1038/s41467-020-19600-4
      </pub-id>
      <pub-id pub-id-type="pmid">
       33247094
      </pub-id>
      <pub-id pub-id-type="pmcid">
       7695829
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3cXisFShtbjO
      </pub-id>
      <elocation-id>
       6084
      </elocation-id>
     </mixed-citation>
    </ref>
    <ref id="CR25">
     <label>
      25.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Tian
        </surname>
        <given-names>
         Y
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Calculating the starting age for screening in relatives of patients with colorectal cancer based on data from large nationwide data sets
      </article-title>
      <source>
       Gastroenterology
      </source>
      <year>
       2020
      </year>
      <volume>
       159
      </volume>
      <fpage>
       159
      </fpage>
      <lpage>
       168.e3
      </lpage>
      <pub-id pub-id-type="doi">
       10.1053/j.gastro.2020.03.063
      </pub-id>
      <pub-id pub-id-type="pmid">
       32251666
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR26">
     <label>
      26.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Chen
        </surname>
        <given-names>
         X
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Personalized initial screening age for colorectal cancer in individuals at average risk
      </article-title>
      <source>
       JAMA Netw. Open
      </source>
      <year>
       2023
      </year>
      <volume>
       6
      </volume>
      <fpage>
       e2339670
      </fpage>
      <pub-id pub-id-type="doi">
       10.1001/jamanetworkopen.2023.39670
      </pub-id>
      <pub-id pub-id-type="pmid">
       37878311
      </pub-id>
      <pub-id pub-id-type="pmcid">
       10600582
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR27">
     <label>
      27.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Qaseem
        </surname>
        <given-names>
         A
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Screening for colorectal cancer in asymptomatic average-risk adults: a guidance statement from the American College of Physicians (Version 2)
      </article-title>
      <source>
       Ann. Intern. Med.
      </source>
      <year>
       2023
      </year>
      <volume>
       176
      </volume>
      <fpage>
       1092
      </fpage>
      <lpage>
       1100
      </lpage>
      <pub-id pub-id-type="doi">
       10.7326/M23-0779
      </pub-id>
      <pub-id pub-id-type="pmid">
       37523709
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR28">
     <label>
      28.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Sun
        </surname>
        <given-names>
         BB
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Plasma proteomic associations with genetics and health in the UK Biobank
      </article-title>
      <source>
       Nature
      </source>
      <year>
       2023
      </year>
      <volume>
       622
      </volume>
      <fpage>
       329
      </fpage>
      <lpage>
       338
      </lpage>
      <pub-id pub-id-type="doi">
       10.1038/s41586-023-06592-6
      </pub-id>
      <pub-id pub-id-type="pmid">
       37794186
      </pub-id>
      <pub-id pub-id-type="pmcid">
       10567551
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3sXitVGqsbbJ
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR29">
     <label>
      29.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Ritchie
        </surname>
        <given-names>
         ME
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       limma powers differential expression analyses for RNA-sequencing and microarray studies
      </article-title>
      <source>
       Nucleic Acids Res.
      </source>
      <year>
       2015
      </year>
      <volume>
       43
      </volume>
      <fpage>
       e47
      </fpage>
      <pub-id pub-id-type="doi">
       10.1093/nar/gkv007
      </pub-id>
      <pub-id pub-id-type="pmid">
       25605792
      </pub-id>
      <pub-id pub-id-type="pmcid">
       4402510
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR30">
     <label>
      30.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Fernandez-Rozadilla
        </surname>
        <given-names>
         C
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries
      </article-title>
      <source>
       Nat. Genet.
      </source>
      <year>
       2023
      </year>
      <volume>
       55
      </volume>
      <fpage>
       89
      </fpage>
      <lpage>
       99
      </lpage>
      <pub-id pub-id-type="doi">
       10.1038/s41588-022-01222-9
      </pub-id>
      <pub-id pub-id-type="pmid">
       36539618
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38XjtFCktr7L
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR31">
     <label>
      31.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Privé
        </surname>
        <given-names>
         F
        </given-names>
       </name>
       <name>
        <surname>
         Arbel
        </surname>
        <given-names>
         J
        </given-names>
       </name>
       <name>
        <surname>
         Vilhjálmsson
        </surname>
        <given-names>
         BJ
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       LDpred2: better, faster, stronger
      </article-title>
      <source>
       Bioinformatics
      </source>
      <year>
       2021
      </year>
      <volume>
       36
      </volume>
      <fpage>
       5424
      </fpage>
      <lpage>
       5431
      </lpage>
      <pub-id pub-id-type="doi">
       10.1093/bioinformatics/btaa1029
      </pub-id>
      <pub-id pub-id-type="pmid">
       33326037
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR32">
     <label>
      32.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Kuhn
        </surname>
        <given-names>
         M
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Building predictive models in R using the caret package
      </article-title>
      <source>
       J. Stat. Softw.
      </source>
      <year>
       2008
      </year>
      <volume>
       28
      </volume>
      <fpage>
       1
      </fpage>
      <lpage>
       26
      </lpage>
      <pub-id pub-id-type="doi">
       10.18637/jss.v028.i05
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR33">
     <label>
      33.
     </label>
     <mixed-citation publication-type="other">
      Gerds, T., Ohlendorff, J. &amp; Ozenne, B.
      <italic>
       riskRegression: risk regression models and prediction scores for survival analysis with competing risks
      </italic>
      . R package version 2023.09.08 (2023).
      <ext-link ext-link-type="uri" xlink:href="https://CRAN.R-project.org/package=riskRegression">
       https://CRAN.R-project.org/package=riskRegression
      </ext-link>
      .
     </mixed-citation>
    </ref>
    <ref id="CR34">
     <label>
      34.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Vickers
        </surname>
        <given-names>
         AJ
        </given-names>
       </name>
       <name>
        <surname>
         Elkin
        </surname>
        <given-names>
         EB
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Decision curve analysis: a novel method for evaluating prediction models
      </article-title>
      <source>
       Med. Decis. Mak.
      </source>
      <year>
       2006
      </year>
      <volume>
       26
      </volume>
      <fpage>
       565
      </fpage>
      <lpage>
       574
      </lpage>
      <pub-id pub-id-type="doi">
       10.1177/0272989X06295361
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR35">
     <label>
      35.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Liese
        </surname>
        <given-names>
         AD
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Assessing the impact of classical risk factors on myocardial infarction by rate advancement periods
      </article-title>
      <source>
       Am. J. Epidemiol.
      </source>
      <year>
       2000
      </year>
      <volume>
       152
      </volume>
      <fpage>
       884
      </fpage>
      <lpage>
       888
      </lpage>
      <pub-id pub-id-type="doi">
       10.1093/aje/152.9.884
      </pub-id>
      <pub-id pub-id-type="pmid">
       11085401
      </pub-id>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:STN:280:DC%2BD3M%2FkslCrtg%3D%3D
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR36">
     <label>
      36.
     </label>
     <mixed-citation publication-type="other">
      Zheng, Y. et al. Use of breast cancer risk factors to identify risk-adapted starting age of screening in China.
      <italic>
       JAMA Netw. Open
      </italic>
      <bold>
       5
      </bold>
      , e2241441 (2022).
     </mixed-citation>
    </ref>
   </ref-list>
  </ref-list>
  <app-group>
   <app id="App1" specific-use="web-only">
    <sec id="Sec29">
     <title>
      Ujuzi wa kushiriki
     </title>
     <p id="Par40">
      <supplementary-material content-type="local-data" id="MOESM1" xlink:title="Supplementary information">
       <media mime-subtype="pdf" mimetype="application" xlink:href="MediaObjects/41467_2024_52894_MOESM1_ESM.pdf">
        <caption xml:lang="en">
         <p>
          Supplementary Information
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM2" xlink:title="Supplementary information">
       <media mime-subtype="pdf" mimetype="application" xlink:href="MediaObjects/41467_2024_52894_MOESM2_ESM.pdf">
        <caption xml:lang="en">
         <p>
          Peer Review File
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM3" xlink:title="Supplementary information">
       <media mime-subtype="pdf" mimetype="application" xlink:href="MediaObjects/41467_2024_52894_MOESM3_ESM.pdf">
        <caption xml:lang="en">
         <p>
          Description of Additional Supplementary Files
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM4" xlink:title="Supplementary information">
       <media mime-subtype="vnd.ms-excel" mimetype="application" xlink:href="MediaObjects/41467_2024_52894_MOESM4_ESM.xlsx">
        <caption xml:lang="en">
         <p>
          Supplementary Data 1-9
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM5" xlink:title="Supplementary information">
       <media mime-subtype="pdf" mimetype="application" xlink:href="MediaObjects/41467_2024_52894_MOESM5_ESM.pdf">
        <caption xml:lang="en">
         <p>
          Reporting Summary
         </p>
        </caption>
       </media>
      </supplementary-material>
     </p>
    </sec>
    <sec id="Sec30">
     <title>
      Data ya kuanza
     </title>
     <p id="Par41">
      <supplementary-material content-type="local-data" id="MOESM6" xlink:title="Source data">
       <media mime-subtype="vnd.ms-excel" mimetype="application" xlink:href="MediaObjects/41467_2024_52894_MOESM6_ESM.xlsx">
        <caption xml:lang="en">
         <p>
          Source Data
         </p>
        </caption>
       </media>
      </supplementary-material>
     </p>
    </sec>
   </app>
  </app-group>
  <notes notes-type="ESMHint">
   <title>
    Ujuzi wa kushiriki
   </title>
   <p>
    The online version contains supplementary material available at
    <ext-link ext-link-type="doi" xlink:href="10.1038/s41467-024-52894-2">
     https://doi.org/10.1038/s41467-024-52894-2
    </ext-link>
    .
   </p>
  </notes>
  <notes notes-type="Misc">
   <p>
    <bold>
     Publisher’s note
    </bold>
    Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
   </p>
  </notes>
 </back>
</article>
